Osteocalcin, N-MID

Osteocalcin, N-MID (also referred to as Bone Gla protein [BGP], N-osteocalcin, or OC) is used to estimate osteoporosis risk in peri- and postmenopausal women and to monitor bone metabolism during hormone replacement therapy or treatment with gonadotropin-releasing hormone agonists. The marker is applied to track bone turnover in patients with growth hormone deficiency, hypothyroidism or hyperthyroidism, and chronic kidney disease. It is commonly repeated 3–6 months after starting antiresorptive therapy to assess treatment response.

Osteocalcin is a principal vitamin K–dependent, noncollagenous protein of the bone matrix that binds calcium and hydroxyapatite. It is synthesized by osteoblasts and odontoblasts; the majority becomes incorporated into the extracellular matrix and mineralizes as new bone, while a fraction circulates in blood. The N-MID assay targets a stable N-terminal midfragment of osteocalcin. During bone resorption, osteoclast-mediated degradation releases osteocalcin fragments that enter the bloodstream and are cleared by the kidneys; consequently, serum concentrations are influenced in part by renal function. At high concentrations, parathyroid hormone suppresses osteoblast activity and osteocalcin synthesis, reducing levels, whereas vitamin D3 stimulates synthesis; calcitonin and calcitriol also modulate regulation. Thus, circulating osteocalcin reflects bone turnover and aids in the assessment of metabolic bone disorders.